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Abstract  35 
 36 
Clinical and molecular studies have implicated epidermal growth factor receptor (EGFR), 37 
insulin-like growth factor (IGF) and target of rapamycin (mTOR) signaling pathways in  38 
the regulation of pancreatic neuroendocrine tumor (PanNET) growth. Interpretation and  39 
comparison of these studies is complex due to clinical and molecular tumor 40 
heterogeneity. We therefore focused in this study on insulinomas, which we examined for 41 
mRNA and protein expression of EGFR, IGF and mTOR signaling pathway components by 42 
quantitative real-time PCR (n=48) and immunohistochemistry (n=86). Findings were 43 
compared with normal pancreatic islets and correlated with histopathological data and 44 
clinical outcome. Insulinomas showed low EGFR and high IGF2 expression. IGFBP2, 45 
IGFBP3 and IGFBP6 mRNA levels were 2-4 folds higher than in islets. High protein 46 
expression of IGF2, IGF1R and INSR (in 51-92% of the tumors) and low to moderate 47 
expression of mTORC1 pathway proteins p-S6k and p-4EBP1 (7-28% of the tumors) were 48 
observed. Correlations were found between 1) ERK1 mRNA expression and that of 49 
numerous IGF pathway genes, 2) p-ERK and IGF1R protein expression and 3) decrease 50 
of IGF pathway components and both metastatic disease and shorter 10 years disease 51 
free survival. In conclusion, our observations suggest that high expression of IGF 52 
signaling pathway components is a hallmark of insulinomas, but does not necessarily 53 
lead to increased mTOR signaling. Reduced expression of IGF pathway components may 54 
be an adverse prognostic factor in insulinomas. 55 
 56 
Introduction  57 
 58 
Over the past years advances have been made in understanding the biology and clinical 59 
behavior of gastroenteropancreatic neuroendocrine tumors (GEP-NETs), a heterogeneous 60 
group of tumors arising from the diffuse neuroendocrine system (Oberg 2012, Muniraj et 61 
al. 2013). The estimated annual incidence of NETs in the USA increased 6.4 fold between 62 
Page 2 of 35
3 
 
1973 and 2012, with an incidence rate of 3.56/100,000 in gastroenteropancreatic sites 63 
(Dasari et al. 2017). GEP-NETs can be divided, based on clinical manifestations, into 64 
functioning (syndrome-related) and non-functioning tumors. Today, PanNETs are treated 65 
by surgery, biotherapy, chemotherapy and/or molecular targeted therapy using 66 
multidisciplinary therapeutic management. Since 2011 the FDA approved the mammalian 67 
target of rapamycin (mTOR) inhibitor Everolimus for the treatment of progressive      68 
PanNETs and well-differentiated, non-functional GEP-NETs and lung-NETs (RADIANT-3 69 
and -4 studies) (Yao et al. 2011, Yao et al. 2016). mTOR regulates cell survival, 70 
proliferation and motility, and also senses cell energy status (Gentzler et al. 2012).  71 
Because of the heterogeneity of PanNETs, analysis of the underlying molecular biology is 72 
essential for successful targeted treatment. The basis of positive treatment results for 73 
Everolimus is derived from a number of studies implicating mTOR pathway alterations in 74 
the proliferation of PanNETs. (Jiao et al. 2011) found mutations in the mTOR pathway 75 
genes PTEN and TSC2 in 14% of (non-functioning) PanNETs. Moreover, (Missiaglia et al. 76 
2010) reported downregulation of PTEN and TSC2, inhibitors of the mTOR pathway, in up 77 
to 70% of non-functioning and functioning PanNETs, including insulinomas. Whole 78 
genome sequencing of insulinomas revealed mutations in the gene YY1, a target of 79 
mTOR, in 30% of the tumors (Cao et al. 2013). Finally, several immunohistochemical 80 
studies showed positivity for mTOR pathway proteins p-mTOR (range 60-70%), p-S6K 81 
(40-80%), and p-4EBP1 (30-90%) in GEP-NETs (Kasajima et al. 2011, Zhan et al. 2012, 82 
Qian et al. 2013). However, interpretation and comparison of these studies is complex 83 
due to the fact that GEP-NETS/PanNETs comprise heterogeneous tumor sub-types with 84 
different clinical and molecular characteristics, and studies have used different diagnostic 85 
tools and evaluation criteria to detect alterations in the mTOR pathway. 86 
The mTOR pathway can be activated by various upstream stimuli, including epidermal 87 
growth factor receptor (EGFR) and the insulin-like growth factor (IGF) signaling system, 88 
which play a pivotal role in cancer development and progression. EGFR activation 89 
promotes cell proliferation via MAPK and PI3K signaling routes, and indications for a role 90 
of EGFR signaling in PanNETs have been reported. Immunohistochemical analysis of 91 
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EGFR expression showed positivity in 30-65% of mixed populations of PanNETs 92 
(Srivastava et al. 2001, Papouchado et al. 2005, Bergmann et al. 2009). The IGF 93 
signaling system includes the ligands IGF1 and IGF2, the receptors IGF1R, IGF2R and 94 
insulin receptor (INSR), and 6 IGF binding proteins (IGFBP1 to 6) (Lodhia et al. 2015). 95 
Deregulation of the IGF signaling system, for example by upregulation of IGF1R, IGF2 96 
and IGFBP2, has been reported in several malignancies, including GEP-NETs/PanNETs 97 
and insulinomas (Wulbrand et al. 2000, Dejeux et al. 2009, Ludovini et al. 2009, 98 
Livingstone 2013). 99 
In this study we evaluated mRNA and protein expression patterns of EGFR and IGF 100 
signaling pathway components that may regulate the mTOR pathway, as well as the 101 
mTORC1 pathway downstream effectors p70S6 Kinase (S6K) and 4E-BP1 (4EBP1) in a 102 
large series of insulinomas. Quantitative real-time PCR (qRT-PCR) and 103 
immunohistochemistry (IHC) data were correlated with each other, with histopathology 104 
and with clinical patient and follow-up data.  105 
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Materials and methods  106 
 107 
A detailed description of materials and methods can be found in Supplementary Materials 108 
and Methods. 109 
Patient samples 110 
Detailed data on insulinoma patient’s age, sex, disease stage and tumor grade and size 111 
are provided as Supplementary Table 1 (Jonkers et al. 2007, Marinoni et al. 2014). All 112 
insulinoma patients had hyperinsulinism followed by a hypoglycaemia syndrome. The 113 
initial treatment consisted of surgical removal of the primary tumor, and if present liver 114 
and/or lymph node metastases. Follow-up treatment for patients with metastatic disease 115 
included surgery, Transarterial Embolization or Transarterial Chemoembolization.  The 116 
tumors were all sporadic, not associated with MEN1 syndrome and classified according to 117 
the World Health Organization 2010 staging and grading system. 118 
From 48 insulinoma patients snap frozen tumor tissue was available for RNA analysis,  119 
and from 26 patients also formalin-fixed, paraffin-embedded material.  120 
Two paraffin-embedded tissue micro arrays (TMAs) were available for 121 
immunohistochemical analysis, containing 49 insulinomas (TMA1) and a second TMA with 122 
11 additional insulinomas (TMA2). TMA1 furthermore contained 92 additional PanNETs 123 
(12 gastrinomas, 11 glucagonomas, 10 vipomas and 59 non-functioning PanNETs), of 124 
which data can be found in Supplementary Table 6. Patient material was used according 125 
to the Code for Proper Secondary Use of Human Tissue in The Netherlands 126 
(https://www.federa.org/, update 2011) and according to the cantonal ethics committee 127 
of Bern (KEK-BE 105-2015).  128 
 129 
RNA isolation  130 
Total RNA was isolated from snap frozen insulinomas using the Qiagen RNeasy Mini Kit, 131 
and had a RIN value ≥ 6.5. 132 
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Control MPV™ Total RNA from normal human pancreas, liver, lung and adrenal gland 133 
(Stratagene) and total RNA from normal, single donor human pancreatic islets (a gift of 134 
Dr E. de Koning, Leiden University Medical Center, The Netherlands) were included as 135 
controls. 136 
 137 
Quantitative Real-Time PCR 138 
Total RNA was converted to cDNA using the iScript cDNA Synthesis Kit (Bio-Rad 139 
Laboratories). qRT-PCR reactions were performed using two commercially available SYBR 140 
green mixes, iQTM SYBR® Green Supermix (BioRad) and SensiMixTM SYBR & Fluorescein 141 
Kit (BioLine). All primers (Supplementary Table 2) were purchased from Biolegio .   142 
 143 
Immunohistochemistry 144 
Immunohistochemical staining on freshly cut 4 µm-thick formalin-fixed, paraffin 145 
embedded tissue sections was performed using primary antibodies against EGFR, IGF2, 146 
IGF1R, INSR, p-AKT, p-ERK, p-S6K and 4-EBP1. Detailed information on antibodies and 147 
staining conditions can be found in Supplementary table 3. 148 
Immunohistochemical staining was scored as: 0, absent; 1, weakly positive in ≥10% of 149 
cells; 2, moderately positive in ≥10% of cells, 3, strongly positive in ≥10% of cells. 150 
 151 
Statistical analysis 152 
Statistical analysis was performed using SPSS version 20 (IBM). Mean relative gene 153 
expression levels between groups were compared with the F-test and Student t-test. 154 
Associations between relative gene expression levels and immunostaining levels were 155 
determined using Pearson’s correlation.  All P-values were considered statistically 156 
significant if ≤ 0.05 in two-sided tests.  157 
Survival curves were created using the Kaplan–Meier method, the log-rank test was used 158 
to test for differences between subgroups. Details on assessment of disease free or 159 
overall survival rates can be found in the Supplementary Materials and Methods. Cox-160 
regression was used for multivariate analysis.  161 
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Results  162 
 163 
mRNA expression in insulinomas 164 
Neuroendocrine markers  165 
From 48 insulinomas mRNA was analyzed. To check for the endocrine nature of the 166 
tumors the relative mRNA expression levels of insulin (INS), chromogranin (CGA) and 167 
synaptophysin (SYP) were analyzed by quantitative RT-PCR (qRT-PCR). In addition, 168 
mRNA from normal human tissues (whole pancreas, pancreatic islets, liver, lung and 169 
adrenal gland) was analyzed as controls. Expression levels were normalized to 170 
glucuronidase beta (GUSB), which exhibited the most stable expression level in all 171 
samples after comparing the expression levels of 4 housekeeping genes. 172 
Table 1 shows high mean and median expression levels of INS, CGA and SYP mRNA 173 
(8351, 89 and 2.3 normalized to GUSB, respectively), consistent with the neuroendocrine 174 
character of insulinomas. In normal pancreatic islets the mRNA expression levels of INS, 175 
CGA and SYP were respectively 4151, 15 and 0.5. In normal pancreatic tissue the mRNA 176 
levels for these genes were significantly lower. Normal adrenal mRNA showed a high 177 
expression level of CGA (57) and SYP (1.3), but very low INS expression (0.2). In normal 178 
liver and lung tissue very low mRNA expression levels of CGA, SYP and INS were found 179 
(data not shown; analyses of normal controls were performed three times in duplicate). 180 
When compared to normal pancreatic islets the mean expression levels of INS, CGA and 181 
SYP mRNA in insulinomas showed a 2.0, 6.0 and 4.8 fold increase, respectively (Table 1). 182 
 183 
EGFR, ERK and AKT  184 
Since EGFR signaling via MAPK and AKT pathways has been reported to be active in 185 
PanNETs, we examined the mRNA expression levels of EGFR, ERK1, ERK2 and AKT in the 186 
48 insulinomas. EGFR mRNA expression was low (0.10), with a relative expression of 187 
0.15 as compared to normal pancreatic islets (Table 1). ERK1, ERK2 and AKT mRNA 188 
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expression levels were 1.1, 1.6 and 2.6, respectively. ERK1 expression was at the same 189 
level as in normal pancreatic islets, while the relative expression levels of ERK2 and AKT 190 
showed a 0.3 and 0.2 fold decrease.  191 
  192 
IGF pathway 193 
Table 1 shows the mRNA expression levels of IGF pathway-related genes in insulinomas. 194 
In contrast to very low IGF1 levels, the mean mRNA expression level of IGF2 is 1.5, 195 
which is a 12.4 fold increase compared to normal pancreatic islets (median: 3.5 fold 196 
increase). IGFBP2 has an expression level of 4.8, which is 4.0 fold higher than in normal 197 
pancreatic islets. Despite the fact that IGFBP3 and IGFBP6 showed expression levels of 198 
0.21 and 0.23 (normalized to GUSB), their relative expression was 2-3 folds higher than 199 
in normal pancreatic islets. The other IGF pathway genes showed low expression levels 200 
(0.01-0.2).  201 
 202 
mTOR pathway 203 
The mean mRNA expression levels of MTOR and RPS6KB1 (coding for S6K protein)   204 
(were low (0.01-0.02) in insulinomas, whereas EIF4EBP1 (coding for 4EBP1 protein) is 205 
expressed at the level of GUSB (Table 1). In normal pancreatic islets all 3 genes showed 206 
a 0.4-0.6 fold decreased mRNA expression level.  207 
 208 
In conclusion, insulinomas show low expression levels of EGFR mRNA, high expression of 209 
IGF2, a 2-4 fold increased expression of IGFBP2, IGFBP3 and IGFBP6, and a twofold 210 
reduced expression of MTOR, RPS6KB1 and EIF4EBP1, as compared to pancreatic islets.  211 
 212 
Correlations between mRNA expression patterns 213 
Pearson correlation analysis between mRNA expression levels of different signaling 214 
pathway genes is shown in Supplementary Table 4.  Correlations between substantially 215 
expressed genes include those 1) between ERK 1, ERK2 and AKT and 2) between ERK1 216 
and IGF pathway genes IGFBP2 (inverse correlation), IGFBP6, and all receptors (detailed 217 
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information in supplementary Table 4). IGF2, IGFBP3 (except for SYP) and EIF4EBP1 218 
expression levels did not correlate with the other analyzed genes.  219 
 220 
Protein expression in insulinomas 221 
EGFR, ERK and AKT 222 
Immunostaining was performed on 86 insulinomas, including 26 that were also analyzed 223 
for mRNA expression levels (see above), and 60 cases present as single or duplicate 224 
cores on the TMAs. All tumors were negative for EGFR, which is in agreement with the 225 
low assessed EGFR mRNA expression levels. As a positive control a human premalignant 226 
laryngeal lesion was used, showing strongly positive membranous staining. In normal 227 
human pancreas a low number of acinar cells showed a weakly positive membranous 228 
staining, whereas the islet cells were negative for EGFR (Table 2; Fig. 1, A-C).  229 
Table 2 shows the IHC data for p-AKT and p-ERK. A lung carcinoma harboring a K-ras 230 
exon 2 mutation served as positive controls (Supplementary Figure 1, A and B 231 
respectively). A moderate to strong nuclear p-AKT expression was seen in normal 232 
pancreatic islet cells, whereas the acinar cells were negative. In normal pancreas no p-233 
ERK could be detected. Moderately to strongly positive nuclear p-AKT staining was 234 
observed in 22% and nuclear p-ERK in 32% of insulinomas (Fig. 1, D-F). Twenty-four % 235 
of the insulinomas showed neither nuclear nor cytoplasmic p-ERK staining; 36% were 236 
negative for p-AKT. Moderate to strong simultaneous expression of nuclear p-AKT and p-237 
ERK was found in 10% of the tumors, while in 22% no co-expression of nuclear p-AKT 238 
and p-ERK could be detected (double-negative). 239 
 240 
IGF pathway proteins 241 
IHC results for IGF pathway proteins IGF2 and receptors IGF1R and INSR are shown in 242 
Table 2 and Fig. 1, G-O. In 92% of the insulinomas a strong cytoplasmic, diffusely 243 
granular pattern of IGF2 was observed. A similar pattern of lower intensity was seen in 244 
normal pancreatic islet cells, whereas acinar cells showed a strong, aggregated 245 
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extracellular IGF2 localization, which could be a sign of internalization of IGF1R and/or 246 
INSR after ligand binding (Rajapaksha & Forbes 2015).  247 
Tumors indeed exhibited high, diffuse cytoplasmic expression levels of IGF1R and INSR 248 
(78% and 83%, respectively), while in 51% of the cases also a membranous IGF1R 249 
staining and in 38% a perinuclear localization of INSR was observed.  250 
These patterns could also be recognized in the normal pancreas, i.e. the islet cells 251 
showed a granular cytoplasmic IGF1R and INSR expression pattern, whereas the acinar 252 
compartment showed a membranous IGF1R localization, and a cytoplasmic INSR 253 
expression with perinuclear localization.  254 
These data indicate that the IGF pathway is active in insulinomas.   255 
 256 
mTORC1 pathway proteins p-S6K and p-4EBP1 257 
Table 2 and Figure 2 (A-F) show the IHC results for p-S6K and p-4EBP1. Normal human 258 
colon tissue served as positive control (Supplementary Figure 1, C and D). 259 
In 28% of insulinomas a weakly to moderately positive cytoplasmic p-S6K staining 260 
pattern was seen. Also 28% of tumors showed nuclear staining. Normal pancreatic islets 261 
showed the same staining pattern but with lower intensity. In contrast, in approximately 262 
75% of normal pancreatic acinar cells a moderately to strongly positive perinuclear 263 
and/or diffuse nuclear p-S6K staining was detected. Interestingly, in tumor-adjacent 264 
pancreatic tissue we observed a stronger p-S6K staining in acinar and islet cells than in 265 
normal control pancreatic tissue (data not shown).  266 
Only 37% of insulinomas exhibited a weakly to moderately positive nuclear p-4EBP1 267 
staining, and in 22% also cytoplasmic staining was detected (Table 2). Normal pancreatic 268 
islets did not show p-4EBP1 expression, and areas, predominantly at the periphery of 269 
lobules, showed a moderately to strongly positive diffuse cytoplasmic, and in 90% also 270 
strong nuclear, immunostaining in acinar cells (Fig. 2, D-E). Strikingly, exocrine 271 
pancreatic tissue adjacent to the tumor often displayed a stronger nuclear and 272 
cytoplasmic immunostaining.  273 
 274 
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In conclusion, insulinomas show high expression levels of IGF2, IGF1R and INSR, no 275 
EGFR expression and low levels of phosphorylated mTORC1 pathway proteins.  276 
 277 
Positive correlations between protein expression patterns 278 
Pearson correlation analysis of protein expression levels shows a correlation of 279 
IGF2 with cytoplasmic IGF1R (p=0.019). The latter also correlates with nuclear p-ERK 280 
(p=0.003), which in turn correlates with nuclear p-AKT (p=0.011) and nuclear p-S6K 281 
(p=0.002). In addition cytoplasmic INSR correlates with nuclear p-S6K (p=0.024) 282 
(Supplementary table 5). 283 
 284 
Correlation of mRNA and protein expression with clinicopathologic 285 
parameters in insulinomas 286 
 287 
Mean relative gene expression levels of insulinoma subgroups were compared using 288 
Student’s t-test (Table 3A). Of the 20 genes analyzed, only the relative expression level 289 
of IGF2R compared to normal pancreatic islets was significantly lower in grade 2/3 than 290 
in grade 1 insulinomas (p=0.039). A decrease in expression in grade 2/3 tumors was 291 
also seen for IGF1R, INS and IGF2, although not statistically significant. At the protein 292 
level (Table 3B) a significantly lower membranous INSR and cytoplasmic p-4EBP1 293 
staining intensity was found in grade 2/3 as compared to grade 1 insulinomas (p=0.004 294 
and p=0.001, respectively).  295 
The mean mRNA expression level of INS relative to normal pancreatic islets was 296 
significantly lower in metastatic insulinomas than in non-metastatic (p<0.0001).  In 297 
contrast, the relative expression of IGFBP3 was higher in metastatic tumors, although the 298 
difference was not statistically significant. The protein expression levels of IGF2, 299 
cytoplasmic IGF1R and INSR, membranous INSR and cytoplasmic p-S6K were 300 
significantly lower in metastatic tumors than in non-metastatic tumors (p=0.001, 301 
p=0.026, p=0.035, p=0.004 and p=0.030, respectively). 302 
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Comparison of the mean mRNA expression levels between tumors < and ≥ 2 cm revealed 303 
INS and 4EBP1 mRNA levels to be significantly lower in tumors ≥2cm (p=0.009 and 304 
p=0.003, respectively). This was also observed for IGF2 protein expression (p=0.001).  305 
A higher disease stage (stage IV versus stage I+II) correlated with a lower expression of 306 
INS, IGF2 and IGF1R mRNA, as well as IGF2, p-ERK (nuclear and cytoplasmic), 307 
cytoplasmic IGF1R and in membranous INSR protein. 308 
In conclusion, insulinomas appear to reduce IGF pathway gene expression both at the 309 
mRNA and protein level in relation to tumor grade, metastatic potential, size and disease 310 
stage.  311 
 312 
Correlation of mRNA and protein expression and clinicopathologic 313 
parameters with survival in insulinomas 314 
 315 
Lower mRNA expression levels of INS, IGF1R and INSR-A (p≤0.019 for disease free and 316 
p≤0.032 for overall survival) and higher levels of IGFBP3 (p<0.0001 for disease free and 317 
p=0.001 for overall survival) correlated with shorter 10 years survival (Figure 3 and 318 
suppl. Fig 2). 319 
Lower protein levels of cytoplasmic IGF2, IGF1R and INSR (p≤0.035 for disease free 320 
survival; P≤0.033 for overall survival) correlated with shorter 10 years survival rates (Fig 321 
4 and suppl. Fig 3). 322 
Univariate analysis of clinicopathological parameters of tumors showed very strong 323 
associations of grade, metastatic disease, tumor size and disease stage with both 10 324 
years disease free and overall survival (p<0.0001) (Fig 3 and Supplementary Fig 2 E-H, 325 
and Fig 4 and Suppl Fig 3 D-G).  326 
In Table 4 a summary of parameters that correlate with disease outcome in univariate 327 
analysis results is shown. 328 
When comparing high versus low gene expression of either INS, IGF1R, INSRA or IGFBP3 329 
with grade, metastatic disease and tumor size in multivariate analysis no significant 330 
associations were found. In multivariate analysis of moderate versus high IGF2 protein 331 
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expression, grade and tumor size, grade (p=0.024, HR 6.81) and tumor size (p=0.022, 332 
HR 17.77) were significantly correlated with 10 year survival. When comparing IGF1R 333 
(high versus low expression) with grade and tumor size in multivariate analysis only 334 
tumor size (p=0.032, HR 7.03) correlated with 10 year survival. This was also found 335 
when comparing INSR (high versus low expression) in multivariate analysis with grade 336 
and tumor size (tumor size: p=0.007, HR 9.31).  337 
 338 
Protein expression analysis in PanNETs other than insulinomas  339 
 340 
We also analyzed protein expression in 92 PanNETs other than insulinomas, which were 341 
available on the TMA1. Data evaluation and analysis are available as supplementary data 342 
(Suppl Results, Suppl Tables 6, 7 and 8). 343 
 344 
Discussion  345 
 346 
Since PanNETs are a heterogeneous group of neoplasms, understanding the underlying 347 
molecular biology of the different subgroups is essential to offer adequate treatment 348 
(Cives et al. 2016). Our study focused on mRNA and protein expression of EGFR, IGF and 349 
mTOR signaling pathway components in insulinomas. We found that, compared to 350 
pancreatic islets, insulinomas show low expression levels of EGFR mRNA, high expression 351 
of IGF2, a 2-4 fold increased expression of IGFBP2, IGFBP3 and IGFBP6, and a twofold 352 
reduced expression of MTOR, RPS6KB1 and EIF4EBP1. At the protein level, high 353 
expression levels of IGF2, IGF1R and INSR were detected, whereas no EGFR and 354 
relatively low levels of mTOR pathway proteins were observed. Correlation of expression 355 
data with clinicopathological data revealed a decrease of several IGF pathway 356 
components in relation to tumor grade, metastatic disease, tumor size and disease stage. 357 
Low mRNA expression levels of IGF2, IGF1R and INSR-A but high levels of IGFBP3 358 
correlated with shorter 10 years overall and disease-free survival. Decreased protein 359 
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expression of IGF2, cytoplasmic IGF1R and INSR also correlated with shorter survival 360 
rates.  361 
Activated EGFR enhances tumor growth, invasion and metastatic spread and promotes 362 
cell survival. Abnormal expression of (mutated) EGFR is often found in neoplasms, 363 
particularly in breast, non-small-cell lung, head and neck and colorectal cancer, which is 364 
utilized in targeted therapy with TKIs or antibodies directed against EGFR (Ciardiello & 365 
Tortora 2008, Garraway & Janne 2012). An initial phase II trial using gefitinib treatment 366 
of PanNETs, however, did not show much efficacy, i.e. no objective responses and a 6-367 
months progression-free survival of 10% for islet cell carcinomas (Hobday et al. 2006). 368 
In our study we found low levels of EGFR mRNA and neither detectable protein 369 
expression in insulinomas and normal pancreatic islets. These data thus may explain the 370 
low efficacy of EGFR inhibitors in the treatment of PanNETs. Nevertheless, other studies 371 
have reported detectable expression of EGFR in 18-66% of the tumors (Wulbrand et al. 372 
1998, Srivastava et al. 2001, Fjallskog et al. 2003, Papouchado et al. 2005, Gilbert et al. 373 
2013), with low expression in benign PanNETs and high expression rates in both well-374 
differentiated PanNETs and poorly differentiated pancreatic neuroendocrine carcinomas 375 
(Bergmann et al. 2009). In these studies, however, mixed groups of PanNETs were 376 
subjected to immunohistochemical staining protocols differing in, amongst others 377 
pretreatment steps, primary antibodies, and evaluation criteria. We have utilized a 378 
commonly used EGFR immunostaining protocol and a primary EGFR-specific antibody, 379 
resulting in intense EGFR membrane staining in head and neck premalignancy control 380 
specimens as well as in pancreatic ducts adjacent to negative insulinomas. Based on our 381 
results we can conclude that EGFR signaling does not play a pivotal role in insulinoma 382 
carcinogenesis and progression. 383 
Our most striking finding was that 92% of insulinomas stained moderately to strongly 384 
positive for the IGF2 protein, which implicates autocrine activation of the IGF pathway in 385 
tumorigenesis, also reported by others (Samani et al. 2007, Weroha & Haluska 2012, 386 
Denduluri et al. 2015). This corresponded well with the 12.4 fold higher IGF2 mRNA level 387 
in insulinomas compared to normal pancreatic islets. IGF2 is an imprinted gene, 388 
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expressed primarily from the paternal allele. Methylation of the IGF2 regulatory regions 389 
has been reported in many cancers, resulting in loss of imprinting and protein 390 
overexpression (Murphy et al. 2006, Cerrato et al. 2008, Dejeux et al. 2009, Livingstone 391 
2013, Creemers et al. 2016). (Dejeux et al. 2009) reported hypermethylation of the 392 
differentially methylated region 2 (DMR2) as a specific event in insulinomas, leading, in a 393 
subset of the samples, to IGF2 mRNA overexpression compared to normal pancreatic 394 
tissue, other PanNETs (gastrinomas and non-functioning) and small intestinal endocrine 395 
tumors. At the protein level they found moderate to high expression levels in 14/28 396 
insulinomas. The use of a different primary antibody and unspecified immunostaining 397 
procedure might explain the lower frequency of IGF2 positive insulinomas. (Hoog et al. 398 
2001) detected higher levels of IGF2 protein in 16 out of 18 insulinomas, which is in 399 
accordance with our findings. In contrast to IGF2, the mRNA expression of IGF1 was very 400 
low in insulinomas and not detectable in normal pancreatic islets.  401 
The IGF signaling pathway is activated by binding of the ligands IGF1, IGF2 or insulin to 402 
their respective receptors, IGF1R and INSR. Posttranscriptional alternative splicing of 403 
INSR results in two isoforms, INSR-A (which lacks exon 11) and INSR-B. IGF2 binds with 404 
similar affinity both to IGF1R and INSR-A, which promotes cell growth, proliferation and 405 
survival (Chao & D'Amore 2008). IGF1R and INSR are overexpressed in a variety of 406 
cancers, including breast, prostate, osteosarcoma and thyroid carcinomas (Lodhia et al. 407 
2015). In our study we found moderate to strong cytoplasmic and membranous IGF1R 408 
and cytoplasmic INSR protein expression in 51%, 78% and 83% of the insulinomas 409 
respectively, which was at least similar, or stronger in staining intensity than observed in 410 
pancreatic islets. Since we found a correlation between IGF1R and high IGF2 protein 411 
expression levels, these data suggest the presence of an autocrine proliferative loop in 412 
insulinomas, as described for other cancer types (Bergman et al. 2013, Livingstone 413 
2013). 414 
Binding of IGF1 or IGF2 to IGF1R or INSR leads to autophosphorylation of the β subunit 415 
tyrosine kinase and recruitment of INSR substrates (IRS), inducing activation of the 416 
MAPK/ERK and PI3K/AKT signaling pathways (Alvino et al. 2011). Phosphorylation of AKT 417 
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leads to activation of mTOR and downstream effectors of mTORC1 S6K and 4EBP1, both 418 
regulators of mRNA translation and involved in cell proliferation and survival (Robbins & 419 
Hague 2015). Although 51 and 83% respectively, of the insulinomas in our study express 420 
IGF1R and INSR protein, only 22% and 32% respectively, strongly express nuclear p-421 
AKT and p-ERK, and 4 and 19% respectively, express p-S6K and p-4EBP1. Interestingly, 422 
a positive correlation was found between cytoplasmic IGF1R expression on the one hand 423 
and IGF2 and nuclear p-ERK on the other. Also at the mRNA level a correlation was 424 
observed between AKT, ERK1, RPS6KB1 and MTOR. The fact that IGF1R signaling does 425 
not necessarily results in AKT/mTOR signaling might be the result of an intact PTEN 426 
expression in about two third of the tumors, inhibiting PI3K and subsequent downstream 427 
signaling. Reduced PTEN expression or altered subcellular localization has been reported 428 
to activate PI3K/AKT/mTOR signaling in PanNETs (Perren et al. 2000, Missiaglia et al. 429 
2010), which might have occurred in the remaining one third of the insulinomas in our 430 
study. In a pilot study of 10 cases we indeed observed loss of nuclear PTEN expression, 431 
as compared to normal islets, in 4cases with p-AKT and p-S6K expression (Data not 432 
shown). (Komori et al. 2014) also found active mTOR signaling in 22-35% of a group of 433 
14 insulinomas tested for amongst others p-mTOR, p-S6K and p-4EBP1. The percentage 434 
of tumors exhibiting active AKT/mTOR signaling varies significantly in different studies 435 
due to different PanNET subgroups tested, as well as different antibodies and cut-off 436 
criteria for positivity used (Ghayouri et al. 2010, Kasajima et al. 2011, Qian et al. 2013). 437 
It is tempting to speculate that p-AKT and/or p-S6K are putative predictive markers of 438 
response to Everolimus. A recent study on PanNETs indeed showed anecdotal evidence of 439 
p-AKT for this role in a primary cell culture model for response to Everolimus (Falletta et 440 
al. 2016).  441 
We observed a decreased level of several IGF pathway components in relation to tumor 442 
grade, metastatic disease, tumor size and and disease stage. The protein expression 443 
levels of IGF2, cytoplasmic IGF1R, cytoplasmic and membranous INSR, and cytoplasmic 444 
p-S6K were significantly lower in tumors from patients with metastatic disease than from 445 
those with non-metastatic disease. Also the mean mRNA expression levels of INS was 446 
Page 16 of 35
17 
 
significantly lower in patients with metastatic insulinomas as compared to non-metastatic 447 
insulinomas. This finding is furthermore reflected in the lower levels of these IGF 448 
pathway proteins and their mRNAs in association with shorter 10 years disease-free 449 
survival and overall rates. A decrease in both IGF1R protein and gene expression levels 450 
has been described before in esophageal adenocarcinoma, colorectal and breast cancer 451 
(Schnarr et al. 2000, Allison et al. 2007, Kuklinski et al. 2011, De Bruijn et al. 2015) and 452 
might reflect a dedifferentiation process. Indeed, two recent genomic studies have 453 
identified distinctive m(i)RNA expression profiles, separating PanNET with liver 454 
metastases (metastasis-like primary tumor subtype) from well-differentiated PanNETs 455 
(well-differentiated islet/insulinoma tumor subtype), further underscoring 456 
dedifferentiation to be reflected in gene expression signatures (Sadanandam et al. 2015, 457 
Scarpa et al. 2017). Decreased insulin signaling was one described hallmark of mouse 458 
metastasis like primary PanNET (Sadanandam et al. 2015)). It remains to be studied 459 
whether the changes in gene expression seen in insulinomas reflect a different entity or 460 
are the result of tumor progression. 461 
An interesting finding was that the shorter 10 years overall and disease-free survival 462 
rates also correlated with higher levels of IGFBP3 mRNA in insulinomas. This gene 463 
belongs to a family of 6 IGF binding proteins, which function as transport proteins for 464 
IGF1 and IGF2 in the peripheral circulation, and in this way limit the bioavailability of 465 
IGFs, as well as modulators of cell function via amongst others IGF1R-dependent 466 
mechanisms (Baxter 2014). IGFBP3 has been proposed to function as either tumor 467 
promotor or suppressor (Baxter 2014). On the one hand overexpression is detected in 468 
association with tumor progression in many tumor types, such as head and neck 469 
carcinoma (Marimuthu et al. 2013), melanoma (Xi et al. 2006) or renal clear cell 470 
carcinoma (Takahash et al. 2005), and on the other hand (Ren et al. 2007) found a 471 
higher IGFBP3 mRNA expression in benign as compared to malignant breast tumors. In 472 
agreement with our study, (Hansel et al. 2004) found higher expression levels of IGFBP3 473 
in well differentiated PanNETs of patients with metastatic disease, although this 474 
particularly comprised non-functioning tumors and no metastatic insulinomas were 475 
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included. A high IGFBP3 mRNA expression was also identified in PanNETs of the 476 
metastasis-like primary PanNET subtype in a recent genomic analysis (Scarpa et al. 477 
2017).  478 
In conclusion, our observations suggest that insulinomas are characterized by high 479 
expression levels of IGF signaling pathway components, with a possibility of a strong 480 
autocrine loop especially in benign well-differentiated insulinomas. This IGF-signaling 481 
pathway appears to be downregulated during tumor progression, coinciding with a 482 
shorter 10 years disease free survival. 483 
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Legends to the figures  1 
Figure 1. Representative examples of immunohistochemical EGFR, pAKT, pERK, IGF2, 2 
IGF1R and INSR protein expression in human tissue: normal pancreas (B, D, G, J, M), a 3 
premalignant laryngeal lesion (A) and insulinomas (C, E, F, H, I, K, L, N, O). Strong 4 
membranous EGFR expression in a premalignant laryngeal lesion (A), weakly positive 5 
expression in normal acinar cells, and no detectable expression in the islets (B) and in 6 
insulinomas (C). Moderate to strong nuclear p-AKT expression in normal pancreatic islets 7 
(D), and moderate to strong nuclear and moderate cytoplasmic expression in an 8 
insulinoma (E). Strong nuclear p-ERK immunostaining in an insulinoma (F). Strong 9 
aggregate like, extracellular IGF2 localization in normal acinar cells, and a moderate, 10 
diffuse granular cytoplasmic staining pattern in pancreatic islets (G). Strong, granular 11 
cytoplasmic IGF2 expression in a non-metastatic insulinoma and weakly positive, diffuse 12 
cytoplasmic expression in a metastatic insulinoma (H and I respectively). Strongly 13 
positive, membranous IGF1R expression in normal acinar cells and moderately positive, 14 
granular cytoplasmic expression pattern in islet cells (J). In insulinomas a strong, 15 
cytoplasmic expression (K) or combined cytoplasmic and membranous IGF1R expression 16 
pattern (L) is seen. Moderate to strong cytoplasmic, perinuclear INSR expression in 17 
normal acinar cells with a granular, cytoplasmic pattern in islet cells (M). Moderate, 18 
diffuse granular and strong perinuclear INSR expression (N) or weak to moderate, diffuse 19 
expression (O) in insulinomas. Original magnifications 200X. 20 
Figure 2. Representative examples of immunohistochemical p-S6K and p-4EBP1 protein 21 
expression in normal human pancreatic tissue and insulinomas. Strong, perinuclear 22 
expression pattern of p-S6K in normal acinar cells, while the islets cells show a very 23 
weak, diffuse cytoplasmic expression (A). Weak cytoplasmic and moderate to strong 24 
nuclear expression of p-S6K in insulinoma (B). Moderately to strongly positive diffuse 25 
cytoplasmic and nuclear p-4EBP1 immunostaining in normal exocrine pancreas cells at 26 
the periphery of a lobule (C). No detectable p-4EBP1 expression in normal pancreatic 27 
islet (D). Strong nuclear and weak to moderate cytoplasmic p-4EBP1 expression in tumor 28 
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adjacent exocrine tissue (E). Moderate to strong nuclear and weak cytoplasmic p-4EBP1 29 
expression in insulinoma (F).   30 
 31 
Figure 3. Kaplan-Meier analysis showing 10 year disease-free survival rates of 32 
insulinoma patients with regard to mRNA expression (A-D) and clinicopathological 33 
parameters (E-H). . Correlation between survival and mRNA expression, A: INS (cut off 34 
25th percentile), B: IGF1R (cut off 25th percentile), C: INSR-A (cut off 25th percentile), D: 35 
IGFBP3 (cut off 25th percentile), E: Grade (Grade1 versus Grade 2+3), F: Disease (non-36 
metastatic versus metastatic), G: Tumor size (<2 cm versus ≥2 cm) and H: Disease 37 
stage (Stage I+IIa versus IV). 38 
Dotted lines in plot A-D refer to low expression. 39 
 40 
Figure 4. Kaplan-Meier analysis showing 10 year disease-free survival rates of 41 
insulinoma patients with regard to protein expression (A-C) and clinicopathological 42 
parameters (D-G). Correlation between survival and protein expression, A: IGF2 43 
(moderate (2) vs high (3) expression), B: cytoplasmic IGF1R (low vs high expression), C: 44 
cytoplasmic INSR (low vs high expression), D: Grade (Grade1 versus Grade 2+3), E: 45 
Disease (non-metastatic versus metastatic), F: Tumor size (<2 cm versus ≥2 cm) and G: 46 
Disease stage.  47 
 48 
Suppl. Figure 1. Control immunoperoxidase stainings for p-AKT, p-ERK, p-S6K 49 
and p4-EBP1.Moderate to strong nuclear and weak cytoplasmic expression of p-AKT (A) 50 
and 51 
moderate nuclear expression of p-ERK (B) in a lung tumor harboring a 52 
K-ras exon 2 mutation. Moderate nuclear p-S6K expression (C) and moderate 53 
cytoplasmic p-4EBP1 expression (D) in glandular normal colon cells . 54 
A low percentage of cells also shows a moderate to strong nuclear p-4EBP1 55 
staining pattern (D). Original magnifications 200X. 56 
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Suppl. Figure 2. Kaplan-Meier analysis showing 10 year overall survival rates of 57 
insulinoma patients with regard to mRNA expression (A-D) and clinicopathological 58 
parameters (E-H). Correlation between survival and mRNA expression, A: INS (cut off 59 
25th percentile), B: IGF1R (cut off 25th percentile), C: INSR-A (cut off 25th percentile), 60 
D: IGFBP3 (cut off 25th percentile), E: Grade (Grade1 versus Grade 2+3), F: Disease 61 
(non-metastatic versus metastatic) G: Tumor size (<2 cm versus ≥2 cm) and H: Disease 62 
stage (Stage I+IIa versus IV). Dotted lines in plots A-D refer to low expression. 63 
 64 
Suppl. Figure 3. Kaplan-Meier analysis showing 10 year overall survival rates of 65 
insulinoma patients with regard to protein expression (A-C) and clinicopathological 66 
parameters (D-G). Correlation between survival and protein expression, A: IGF2 67 
(moderate (2) vs high (3) expression), B: cytoplasmic IGF1R (low vs high expression), C: 68 
cytoplasmic INSR (low vs high expression), D: Grade (Grade1 versus Grade 2+3), E: 69 
Disease (non-metastatic versus metastatic), F: Tumor size (<2 cm versus ≥2 cm) and G: 70 
Disease stage. Dotted lines in plots A-C refer to low expression. 71 
 72 
 73 
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 Table 1 Mean mRNA expression levels of neuroendocrine related genes  
and genes in the MAPK/ AKT and IGF pathway in 48 
insulinomas 
normalised to GUSB 
Relative to pancreatic 
islets 
  
      
  
  Mean Std Dev Median Mean Std Dev Median 
CGA 88.91 ± 95.94 59,94 6.04 ± 6.61 3,92 
SYNAPT 2.28 ± 1.92 1,83 4.83 ± 4.31 3,61 
INS 8351.20 ± 8507.11 6269,65 2.01 ± 2.03 1,48 
EGFR 0.10 ± 0.10 0,07 0.15 ± 0.17 0,11 
AKT 2.58 ± 1.45 2,28 0.75 ± 0.45 0,63 
ERK1 1.10 ± 0.73 0,93 1.03 ± 0.64 0,95 
ERK2 1.56 ± 0.89 1,45 0.68 ± 0.49 0,55 
IGF1 0.04 ± 0.13 0,01 NA   
IGF1R 0.11 ± 0.12 0,06 0.82 ± 0.92 0,49 
IGF2 1.46 ± 3.12 0,43 12.44 ± 22.64 3,54 
IGF2R 0.13 ± 0.09 0,11 0.67 ± 0.42 0,58 
IGF bp1 0.03 ± 0.07 0,00 1.63 ± 4.13 0,16 
IGF bp2 4.81 ± 5.69 3,44 4.04 ± 4.41 3,18 
IGF bp3 0.21 ± 0.32 0,09 2.86 ± 4.74 1,24 
IGF bp6 0.23 ± 0.32 0,12 2.03 ± 1.99 1,37 
INSR-A 0.22 ± 0.20 0,19 1.30 ± 0.70 1,27 
INSR-B 0.10 ± 0.09 0,08 0.75 ± 0.54 0,70 
mTOR 0.01 ± 0.01 0,01 0.35 ± 0.44 0,22 
RPS6KB1 0.02 ± 0.02 0,01 0.58 ± 0.61 0,39 
EIF4EBP1 0.84 ± 0.87 0,58   0.45 ± 0.46 0,30 
 
IGF1 relative to pancreatic islets cannot be calculated since IGF1 was not detectable in normal pancreatic 
islets 
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Table 2  Immunohistochemical expression of proteins in the 
EGFR/MAPK/AKT/IGF/mTOR pathways in insulinomas,  
presented as percentage of the samples with a specified 
staining intensity. 

       weakly    
Insulinomas  negative positive  positive 
          
EGFR 100 0 0 
p-AKT nuclear 60 18 22 
p-AKT cytoplasmic 51 41 8 
p-ERK nuclear 30 38 32 
p-ERK cytoplasmic 38 38 24 
IGF2 1 7 92 
IGF1R cytoplasmic 4 18 78 
IGF1R membranous 38 11 51 
INSR cytoplasmic 4 13 83 
p-S6K nuclear 72 9 19 
p-S6K cytoplasmic 72 16 12 
p-4EBP1 nuclear 93 3 4 
p-4EBP1 cytoplasmic 78 13 9 
 
Staining intensity was defined as negative, weakly positive in >10 % 
of cells and moderately or strongly positive in >10 % of cells. 
Abbreviation used: p=phosphorylated 

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Table 4   Significance levels (p-values) for univariate analysis of insulinomas, indicating the 
relation of clinical and molecular parameters with disease outcome for tumors subjected to A 
mRNA expression analysis and B protein expression analysis 
 
 OS DFS  OS DFS 
        A p-value p-value B p-value p-value 
      
Grade1    0.007   0.002 Grade1 <0.0001 <0.0001 
Disease2 <0.0001 <0.0001 Disease2 <0.0001 <0.0001 
Tumor size3    0.003 <0.0001 Tumor size3 <0.0001 <0.0001 
Disease stage4 <0.0001 <0.0001 Disease stage4 <0.0001 <0.0001 
      
INS
5  <0.0001a <0.0001a IGF26    0.027a    0.035a 
IGF1R
5 <0.0001a <0.0001a IGF1R6    0.033a    0.012a 
INSR-A
5
     0.032a    0.0019a INSR6    0.016a    0.010a 
IGFBP3
5
     0.001b <0.0001b    
      
 
 
Abbreviations used: OS, overall survival; DFS, disease free survival 
 1 Grade 1 vs Grade 2+3; 2 non-metastatic vs metastatic disease; 3 tumor size <2 cm vs ≥2 
cm; 4 disease stage I+II vs IV; 5 high vs low mRNA expression (see Figure 2 A-D legend); 6 
high vs low protein expression (see Figure 3 A-C legend). 
a p-values refer to shorter 10 years survival for lower expression; b  p-values refer to shorter 
10 years survival for higher expression 
 
Page 31 of 35
  
 
 
Figure 1  
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Figure 2  
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Figure 3    
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Figure 4    
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